Search Result

Results for "

variants

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Aldose Reductase (1) Aminoacyl-tRNA Synthetase (1) AMPK (1) Amyloid-β (3) Androgen Receptor (9) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (3) Apoptosis (3) Autophagy (2) Bacterial (4) Bcr-Abl (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) Complement System (2) DNA/RNA Synthesis (3) EGFR (4) Endogenous Metabolite (3) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) FLT3 (1) Fungal (6) GCGR (2) GLP Receptor (2) Glutaminase (2) HBV (1) HCV (5) HCV Protease (4) HIV (4) HIV Integrase (1) HIV Protease (7) IGF-1R (1) iGluR (1) Influenza Virus (2) Interleukin Related (3) JNK (2) Ligands for E3 Ligase (1) MDM-2/p53 (1) MNK (1) Molecular Glues (1) Mucin (2) nAChR (1) Neuropeptide Y Receptor (1) NF-κB (1) p38 MAPK (2) Parasite (1) PARP (1) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (2) PI4K (1) Progesterone Receptor (2) PROTACs (2) RABV (1) Raf (2) Ras (3) Reverse Transcriptase (2) Ribosomal S6 Kinase (RSK) (1) RSV (1) SARS-CoV (37) STING (2) Thrombin (1) Transthyretin (TTR) (2) Trk Receptor (1) VEGFR (2) Virus Protease (5)
By Research Areas:	Cancer (37) Cardiovascular Disease (5) Endocrinology (3) Infection (65) Inflammation/Immunology (19) Metabolic Disease (6) Neurological Disease (12)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Phospholipids (1) Antisense Oligonucleotides (4)

129

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

BAY 249716	MDM-2/p53 Bacterial	Infection Cancer
BAY 249716 stabilizes all three p53 protein variants. BAY 249716 also has antitubercular activity (IC₉₀: <0.10 μg/mL for Tuberculosis) .

Pyridoxal 5'-phosphate monohydrate 1 Publications Verification Pyridoxal phosphate monohydrate	Endogenous Metabolite	Neurological Disease
Pyridoxal 5'-phosphate hydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate hydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′‐phosphate (PMP) .

Cergutuzumab amunaleukin CEA-IL2v; RG 7813; RO 6895882	Interleukin Related	Inflammation/Immunology Cancer
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities .

Ledelabricin alfa	Endogenous Metabolite	Inflammation/Immunology
Ledelabricin alfa is a human proteoglycan 4 (PRG4) isoform A variant. PRG4 is a joint/boundary lubricant. Ledelabricin Alfa can be used for the research arthropathy .

Tyrosine kinase-IN-6	c-Met/HGFR	Cancer
Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects .

HIV-1 protease-IN-12	HIV Protease	Infection
HIV-1 protease-IN-12 (compound 35b) is a HIV-1 protease inhibitor with an IC₅₀ of 0.51 nM. HIV-1 protease-IN-12 also inhibits drug-resistant variant .

HIV-1 protease-IN-11	HIV Protease	Infection
HIV-1 protease-IN-11 (compound 34a) is a HIV-1 protease inhibitor with an IC₅₀ of 0.41 nM. HIV-1 protease-IN-11 also exhibits significant activity against drug-resistant variant .

MMT5-14	SARS-CoV	Infection
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC₅₀s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 .

HIV-1 protease-IN-2	HIV Protease	Infection
HIV-1 protease-IN-2 is a potent HIV-1 protease inhibitor with an IC₅₀ of 2.53 nM. HIV-1 protease-IN-2 shows antiviral activity against DRV (Darunavir)-sensitive or DRV-resistant HIV-1 variants .

[D-His26]-Neuropeptide Y, human, rat	Neuropeptide Y Receptor	Neurological Disease
[D-His26]-Neuropeptide Y, human, rat is a synthetic variant of neuropeptide Y (NPY). [D-His26]-Neuropeptide Y, human, rat acts as a Y1R agonist that can prevent the development of anxiety, social impairment, and depressive symptoms, and has the potential to be used as an early intervention treatment for post-traumatic stress reactions .

HIV-1 protease-IN-8	HIV Protease	Infection
HIV-1 protease-IN-8 (compound 34b) is a potent HIV-1 protease inhibitor with an IC₅₀ value of 0.32 nM. HIV-1 protease-IN-8 displays IC₅₀s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1_NL4-3) and drug-resistant variant (HIV-1_MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant .

HIV-1 protease-IN-6	HIV Protease HIV	Infection Inflammation/Immunology
HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC₅₀ of 21 pM and a K_i of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus .

Bofutrelvir FB2001	SARS-CoV	Infection
Bofutrelvir (FB2001) is a SARS-CoV-2 main protease M ^pro inhibitor with an IC₅₀ value of 53 nM and an EC₅₀ value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC₅₀ values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) .

SLC6A8 corrector 1	Others	Metabolic Disease
SLC6A8 corrector 1 is an orally active and brain-penetrant mutant SLC6A8 variant corrector. SLC6A8 corrector 1 can be used for the study of creatine transporter deficiency (CTD) .

SARS-CoV-2-IN-36	SARS-CoV	Infection
SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC₅₀ of 2.37 μM and a K_d of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .

HIV-1 protease-IN-13	HIV Protease	Infection
HIV-1 protease-IN-13 (compound 18d) is a potent HIV-1 protease inhibitor with an IC₅₀ value of 0.54 nM. HIV-1 protease-IN-13 also shows potent activity against HIV-1DRVRS (DRV-resistant mutation) and HIV-1NL4_3 variant (wild type) .

BPR3P0128	SARS-CoV	Infection
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC₅₀ for SARS-CoV-2 and HCoV-229E are 0.62 µM and 0.14 µM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .

Capeserod hydrochloride SL65.0155	5-HT Receptor	Neurological Disease
Capeserod hydrochloride (SL65.0155) is a 5-HT_4(e) receptor partial agonist (K_i=0.6 nM) with potent cognitive enhancing properties. Capeserod hydrochloride acts as a partial agonist in cells expressing 5-HT_4(b) and 5-HT_4(e) splice variants, stimulating cAMP production with IC₅₀ values ??of 244 and 29 nM, respectively. Capeserod hydrochloride is used in the study of memory impairment and dementia .

Telaglenastat 65+ Cited Publications CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

RMC-7977	Ras ERK Raf Ribosomal S6 Kinase (RSK) AMPK Apoptosis PARP	Cancer
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (K_d = 195 nM) and KRAS (G12V) (K_d = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS ^G12C cancer models, and demonstrates good tolerability across various RAS cancer models .

Chitin synthase inhibitor 12	Fungal	Infection Cancer
Chitin synthase inhibitor 12 is a chitin synthase inhibitor. Chitin synthase inhibitor 12 shows excellent inhibitory activity with an IC₅₀ value of 0.16 mM. Chitin synthase inhibitor 12 also is a broad-spectrum antifungal agent and has significantly antifungal activity against drug-resistant fungal variants, such as C. albicans and C. neoformans. Chitin synthase inhibitor 12 can be used for the research of invasive fungal infections (IFIs) .

Chitin synthase inhibitor 10	Fungal	Infection Cancer
Chitin synthase inhibitor 10 is a chitin synthase inhibitor. Chitin synthase inhibitor 10 shows excellent chitin synthase inhibitory activity with an IC₅₀ value of 0.11 mM. Chitin synthase inhibitor 10 also is an antifungal agent and has significantly antifungal activity against drug-resistant fungal variants, such as C. albicans and C. neoformans. Chitin synthase inhibitor 10 can be used for the research of invasive fungal infections (IFIs) .

Eplontersen	Transthyretin (TTR)	Neurological Disease
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .

Eplontersen sodium	Transthyretin (TTR)	Neurological Disease
Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .

SJF-0661	Ligands for E3 Ligase	Cancer
SJF-0661 is a variant of the von Hippel-Lindau (VHL) protein ligand with no targeted degradation ability and can be used as a control reagent for the VHL ubiquitin ligase ligand. SJF-0661 is a variant obtained by inverting the stereocenter of the key hydroxyproline group in the VHL ligand .

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .

PNU‐142721	HIV Reverse Transcriptase	Infection
PNU-142721 is a reverse transcriptase inhibitor and PXR agonist that effectively inhibits various type I HIV variants .

Surzebiclimab BGB-A425	Mucin	Cancer
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (K_D=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .

Bac2A TFA	Fungal	Infection
Bac2A TFA is an antimicrobial and immunomodulatory peptide. Bac2A TFA is a linear variant of bactenecin and is very effective against fungal pathogens.

Tadnersen sodium BIIB078 sodium; IONIS-C9Rx sodium	Others Ras	Neurological Disease
Tadnersen sodium, an antisense oligonucleotide (ASO), selectively targets *C9ORF72* transcript variants 1 and 3 that carry the expansion .

Medroxyprogesterone-d3 17α-Hydroxy-6α-methylprogesterone-d₃; U8840-d₃	Progesterone Receptor	Endocrinology
Medroxyprogesterone-d₃ is the deuterium labeled Medroxyprogesterone. Medroxyprogesterone is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.

Ac-IHIHIYI-NH2 TFA	Biochemical Assay Reagents	Others
Ac-IHIHIYI-NH2 TFA is an amyloid self-assembling peptide variant that can be used as a bioactive nanomaterial with esterase activity .

Tadnersen BIIB078; IONIS-C9Rx	Ras Others	Neurological Disease
Tadnersen (BIIB078), an antisense oligonucleotide (ASO), selectively targets *C9ORF72* transcript variants 1 and 3 that carry the expansion .

Influenza A virus-IN-8 S5	Influenza Virus	Infection Cancer
Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC₅₀s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a K_d of 1.0 nM .

Casirivimab REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .

Crovalimab SKY59; RO7112689	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

L-Primapterin 7-Biopterin	Endogenous Metabolite	Metabolic Disease
L-Primapterin (7-Biopterin) is the 7-isomer of L-biopterin. L-Primapterin is a characteristic marker of hyperphenylalaninemia variant primapterinuria, which is excreted in the urine .

PBD-150	Amyloid-β	Neurological Disease
PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a K_i value of 490 nM .

Aurodox X 5108; Goldinomycin	Antibiotic Bacterial	Infection
Aurodox (X 5108) is an antibiotic obtained from a streptomyces variant, Aurodox can against a number of gram-positive bacteria. Aurodox shows a very low toxicity in mice and promoted poultry growth .

Adintrevimab 1 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

OVA-E1 peptide	p38 MAPK JNK	Inflammation/Immunology
OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes .

Ensituximab Anti-MUC5AC Reference Antibody (ensituximab); NEO-102	Mucin Others	Cancer
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

Cat. No.	Product Name	Target	Research Area

HY-P3158

TCTDSTNCYKAT	Peptides	Others
TCTDSTNCYKAT is an engineered-variant peptide of antifreeze protein (AFP) .

HY-P10620

GGGYK-Biotin	Peptides	Others
GGGYK-Biotin is a substrate peptide designed to study the substrate specificity of Sortase A. GGGYK-Biotin can be used to develop Sortase A variants with different substrate specificities .

HY-P6079A

Ac-IHIHIYI-NH2 TFA	Biochemical Assay Reagents	Others
Ac-IHIHIYI-NH2 TFA is an amyloid self-assembling peptide variant that can be used as a bioactive nanomaterial with esterase activity .

HY-P4510

SLSLSPG	Peptides	Others
SLSLSPG can be obtained from the C-end of the heavy chain of human Igγ-1. SLSLSPG is a common variant in IgG .

HY-P1138

Scrambled 10Panx FSVYWAQADR	Peptides	Others
Scrambled 10Panx (FSVYWAQADR) is a random sequence variant of a specific inhibitory peptide 10Panx targeted at the half-channel of Pannexin-1 (Panx1). Scrambled 10Panx is used as a control peptide to determine whether other experimental conditions or peptides act through specific molecular mechanisms. Scrambled 10Panx can be used for research in neurobiology and cell biology .

HY-P10545

[D-His26]-Neuropeptide Y, human, rat	Neuropeptide Y Receptor	Neurological Disease
[D-His26]-Neuropeptide Y, human, rat is a synthetic variant of neuropeptide Y (NPY). [D-His26]-Neuropeptide Y, human, rat acts as a Y1R agonist that can prevent the development of anxiety, social impairment, and depressive symptoms, and has the potential to be used as an early intervention treatment for post-traumatic stress reactions .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P5406

OVA-A2 Peptide SAINFEKL, OVA (257-264) Variant	Peptides	Others
OVA-A2 Peptide (SAINFEKL, OVA (257-264) Variant) is a biological active peptide. (A2 peptide (SAINFEKL) is a (OVA) peptide (257-264) variant with antigenic effect.)

HY-P5408

OVA-Q4H7 Peptide SIIQFEHL, OVA (257-264) Variant	Peptides	Others
OVA-Q4H7 Peptide (SIIQFEHL, OVA (257-264) Variant) is a biological active peptide. (Q4H7 Peptide (SIIQFEHL) is a variant of the agonist ovalbumin (OVA) peptide (257-264), SIINFEKL, the strongest positive selecting ligand.)

HY-P2318

Bac2A TFA	Fungal	Infection
Bac2A TFA is an antimicrobial and immunomodulatory peptide. Bac2A TFA is a linear variant of bactenecin and is very effective against fungal pathogens.

HY-149034

Influenza A virus-IN-8 S5	Influenza Virus	Infection Cancer
Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC₅₀s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a K_d of 1.0 nM .

HY-P5411

OVA-T4 Peptide SIITFEKL, OVA (257-264) Variant	Peptides	Others
OVA-T4 Peptide (SIITFEKL, OVA (257-264) Variant) is a biological active peptide. (T4 peptide (SIITFEKL) is a variant of the agonist ovalbumin (OVA) peptide (257-264), SIINFEKL. OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC).)

HY-P2319

OVA-E1 peptide	p38 MAPK JNK	Inflammation/Immunology
OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes .

HY-P2319A

OVA-E1 peptide TFA	p38 MAPK JNK	Inflammation/Immunology
OVA-E1 peptide TFA, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes .

HY-P1771

OVA G4 peptide	Peptides	Inflammation/Immunology
OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P1771A

OVA G4 peptide TFA	Peptides	Inflammation/Immunology
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P3604

LH-RH II (chicken)	Androgen Receptor	Endocrinology
LH-RH II (chicken) is one of the two forms of luteinizing hormone-releasing hormone (LHRH) the hypothalamus of the domestic hen, which are structural variants of mammalian LHRH. LH-RH II (chicken) enhances gonadotrophin release in the domestic chicken .

HY-P3627

Nagrestipen	Peptides	Cancer
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis .

HY-P2258

Histone H3 (1-34)	Peptides	Others
Histone H3 (1-34) is a peptide derived from human histone isotype 3.1. Histones are the main protein components of eukaryotic chromatin. Histone variants and histone modifications modulate chromatin structure, ensuring the precise operation of cellular processes associated with genomic DNA .

HY-P2454

CSP1	Bacterial	Infection
CSP1 is a potent and selective ComD1 receptor agonist, with an IC₅₀ of 10.3 nM. CSP1 is a major variants of competence-stimulating peptide (CSP), and it can regulate genetic transformation of S. pneumonia by modulating quorum sensing (QS). CSP1 can act as an antibacterial agent .

HY-P4889

(Gly22)-amyloid beta-protein(1-40)	Peptides	Neurological Disease
(Gly22)-amyloid beta-protein(1-40) (Arctic variant Ab40ARC (E22G)) is a peptide. (Gly22)-amyloid beta-protein(1-40) can be used for the research of Alzheimer's disease .

HY-P3229

SN52 2 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-P5370

Scrambled β-amyloid (1-40)	Amyloid-β	Others
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P10581A

SIIVFEKL TFA	Peptides	Inflammation/Immunology
SIIVFEKL TFA is a variant of the major MHC class I-restricted epitope SIINFEKL. SIIVFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cells. SIIVFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells .

HY-P10582A

SIYNFEKL TFA	Peptides	Inflammation/Immunology
SIYNFEKL TFA is a variant of major MHC class I-restricted epitope SIINFEKL. SIYNFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cell. SIYNFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells .

HY-P5410

OVA-Q4 Peptide	Peptides	Others
OVA-Q4 Peptide is a biological active peptide. (Q4 Peptide (SIIQFEKL) is a variant of the agonist ovalbumin (OVA) peptide (257-264), SIINFEKL. OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC).)

HY-P5815

GLP-1 (1-36) amide (human, rat) Glucagon-like Peptide 1 (1-36) amide (human, rat)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-P5815A

GLP-1 (1-36) amide (human, rat) (TFA) Glucagon-like Peptide 1 (1-36) amide (human, rat) (TFA)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

Cat. No.	Product Name

HY-K3014

Bi-27 Supplement (50×), Vitamin A-Free, Sterile
Bi-27 Additive (50×), Vitamin A-Free is a customized variant of the standard Bi-27 formulation with vitamin A removed as a supplement for neuronal cell culture to support the low- or high-density growth and short- or long-term viability of embryonic.

Cat. No.	Product Name	Target	Research Area

HY-P99498

Cergutuzumab amunaleukin CEA-IL2v; RG 7813; RO 6895882	Interleukin Related	Inflammation/Immunology Cancer
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities .

HY-P99346

Regdanvimab CT-P59	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .

HY-P99962

Surzebiclimab BGB-A425	Mucin	Cancer
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (K_D=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .

HY-P99341

Casirivimab REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .

HY-P99965

Crovalimab SKY59; RO7112689	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-P99423

Adintrevimab 1 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

HY-P99362

Ensituximab Anti-MUC5AC Reference Antibody (ensituximab); NEO-102	Mucin Inhibitory Antibodies	Cancer
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .

HY-P99811

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

HY-P99690

Ledelabricin alfa	Endogenous Metabolite	Inflammation/Immunology
Ledelabricin alfa is a human proteoglycan 4 (PRG4) isoform A variant. PRG4 is a joint/boundary lubricant. Ledelabricin Alfa can be used for the research arthropathy .

HY-P99633

Garivulimab BGB-A333	PD-1/PD-L1 Apoptosis	Cancer
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P99786

Pozelimab REGN3918	Complement System	Metabolic Disease
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .

HY-P99902

Simlukafusp alfa FAP-IL2v	Interleukin Related	Cancer
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .

HY-P99103

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99342

Imdevimab REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P99496

Cendakimab RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P990782

Efzofitimod	Aminoacyl-tRNA Synthetase	Inflammation/Immunology
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .

Cat. No.	Product Name		Classification

HY-19476

AG-7404		Alkynes
AG-7404 is an inhibitor of picornaviral 3C protease, with anti-poliovirus activity (EC₅₀=0.080-0.674 μM). AG-7404 has synergy with V-073 (HY-104074) or BTA798 (HY-106254), and fully inhibits all V-073-resistant variants . AG-7404 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-125810

4'-Ethynyl-2'-deoxyadenosine		Alkynes
4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside reverse transcriptase (RT) inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC₅₀ of 98 nM in MT-4 cells for anti-HIV-1 activity . 4'-Ethynyl-2'-deoxyadenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-148089A

Eplontersen sodium		Antisense Oligonucleotides
Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .

HY-132581A

Tadnersen sodium BIIB078 sodium; IONIS-C9Rx sodium		Antisense Oligonucleotides
Tadnersen sodium, an antisense oligonucleotide (ASO), selectively targets *C9ORF72* transcript variants 1 and 3 that carry the expansion .

HY-148089

Eplontersen		Antisense Oligonucleotides
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases .

HY-132581

Tadnersen BIIB078; IONIS-C9Rx		Antisense Oligonucleotides
Tadnersen (BIIB078), an antisense oligonucleotide (ASO), selectively targets *C9ORF72* transcript variants 1 and 3 that carry the expansion .

HY-157675

1,2-Dinervonoyl-sn-glycero-3-phosphocholine		Phospholipids
1,2-Dinervonoyl-sn-glycero-3-phosphocholine (24:1 cis PC), characterized by its two 24-carbon fatty acid chains, each featuring a cis double bond at the 15th carbon, is believed to play a role in neuronal differentiation signaling. Avanti offers a diverse range of phosphatidylcholine products, designed to exhibit various physical properties, including short-chain (C3-C8) options that are water-soluble and hygroscopic, as well as saturated, multi-unsaturated, and mixed acid variants. All products undergo HPLC purification, with stringent measures implemented to prevent oxidation and hydrolysis.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

variants

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products